Vetter Launches New US Facility for Clinical Trial Materials
The German fill-finish provider Vetter inaugurated a new US facility in Skokie, IL, just outside Chicago, along with a new subsidiary, Vetter Development Services USA Inc.
The German fill-finish provider Vetter inaugurated a new US facility in Skokie, IL, just outside Chicago, along with a new subsidiary, Vetter Development Services USA Inc. When complete, the new facility will be able to carry out fill-finish operations for small quantities of clinical trial materials.
Although currently only office space is ready, the 24,000 square-foot facility will ultimately include two laboratories (a microbiology laboratory and a quality control laboratory), and three cleanrooms, which are expected to open in the fourth quarter of 2010.
Vetter celebrates the launch of the company’s new small-scale fill-finish facility in Skokie, IL. Pictured (L-R): Wolfgang Kerkhoff, Executive Committee, Vetter; David Miller, President and CEO, Illinois Biotechnology Industry Organization (iBIO); Oskar Gold (at rear), Vice President, Key Account Management, Vetter, Udo J. Vetter, Executive Committee, Vetter; Donald E. Morel, Jr., PhD (at rear), President and CEO, West Pharmaceutical Services, Inc.; Claudia Roth, PhD, Director of Development Services, Vetter; Peter Soelkner, Managing Director, Vetter; Dennis Sienko (at rear), Senior Advisor to the Director, Illinois Department of Commerce and Economic Opportunity; Gunther Strothe, Executive Committee, Vetter, Thomas Otto (at rear), Managing Director, Vetter; Max Horn, Managing Director, Vetter; Michael Rosen, Senior Vice President, New Business Development, Forest City Science + Technology Group.
The first cleanroom will include a semi-automated filling line for a variety of packaging forms, from vials to dual-chamber syringes, capable of filling 500 to 600 items per batch, for Phase 1 and 2 clinical trials. "This highly flexible line is designed for small-scale fills, for example for proof of principle studies," said Peter Soelkner, managing director of Vetter. "For example, a company might want to fill a small quantity to test whether a given formulation will be stable in a certain presentation, or be well accepted by patients.
A second cleanroom will include a state-of-the-art Bosch filling system that was launched earlier this year at Achema. "This system allows you to control filling almost to the last drop, to minimize product loss," said Soelkner. "That is particularly important in early stages of clinical development, when often only very small quantities of drug are available."
The third cleanroom will include a filling line for higher quantities of single-chamber syringes.
Soelkner said the US-based plant would bring Vetter closer to its core customer base. "Two thirds of the drugs in Phase 1 and 2 clinical trials come out of North America," he said. "Being on the same continent will make it easier for them to work with us."
In deciding where to locate the plant, Soelkner said the logistics were important. The new facility is located in the Illinois Science & Technology Park in Skokie, IL, a 20-minute cab ride from Chicago's O'Hare airport, making it easy to reach from the East and West coasts of the US.
The readiness of the facility was another factor, Soelkner said. The facility was previously owned by Pfizer, and had already been revamped by Forest City, the owners of the technology park. "This will enable us to get the facility ready quite quickly," he said.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
Exploring New and Improved Analytical Methods for Traditional and Unique Modalities
December 12th 2024Biophysical characterization is critical to understand the make-up and behaviors of biologic therapies and vaccines, both early in development and throughout the manufacturing scale-up process. As biologics become more complex in structure, and as scientists improve their understanding of the effects of structure on stability, efficacy, safety, etc., there is a need to develop new and improved analytical methods to characterize biologic products. During this presentation, experts will discuss the latest challenges in biophysical characterization and will present solutions to overcome these challenges.
Leveraging Novel Analytical Approaches For Advanced Therapies
December 12th 2024The characterization and analysis of advanced therapies, such as cell and gene therapies (CGTs) can be difficult, as these products are designed to function using complex mechanisms of action (MOA)s. There are a wide range of challenges associated with accurately assessing the potency and impurity profiles of these complex biologicals. As many CGT programs qualify for accelerated review pathways, novel approaches for analysis and characterization can help generate data that allows for real-time decision making and faster development timelines. Catalent has developed a relative potency bioassay using quantitative polymerase chain reaction (qPCR) to assess relative transcription activity in cells treated with ligands or transgenic vectors. The assay platform can be used to qualify a repeatable, accurate, linear, and specific bioassay for assessing relative potency for CGTs, mRNA- and other nucleic acid-based therapies.
